Floatz logo

Anti-Cd7 Car-Pnk Cells

T-cell Prolymphocytic Leukemia

PersonGen BioTherapeutics (Suzhou) Co., Ltd.Cell therapyPhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the T-cell Prolymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2BB
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 2BB
Fludarabine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BB
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BB

View all 29 →

Same molecule, other indications

Anti-Cd7 Car-Pnk Cells is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
CCC
Indicative ·
48 / 100
View asset →
T-cell large granular lymphocyte leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →